Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)
May 14, 2024 8:47 AM EDTBofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $5.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).
The analyst comments "FULC announced the company has entered an exclusive license agreement with Sanofi (ticker: SNY; covered by Graham Perry) for the ex-US development of losmapimod in... More
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
May 13, 2024 12:31 PM EDTStifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $22.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "Ph.3 REACH (facioscapulohumeral muscular dystrophy [FSHD]) data in 4Q24 are the main focus for FY2024, and we're... More
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 1c, provides guidance
May 13, 2024 7:25 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.43), $0.01 better than the analyst estimate of ($0.44).
Update to Cash Runway Guidance
Based on its current operating plans, Fulcrum now expects that its cash, cash equivalents, and marketable securities as of March 31, 2024,... More
